APRI (Aprinoia Therapeutics) Debt-to-EBITDA : -0.54 (As of Dec. 2023)


What is Aprinoia Therapeutics Debt-to-EBITDA?

Aprinoia Therapeutics APRI Debt-to-EBITDA is -0.54 as of Dec. 2023.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aprinoia Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.78 Mil. Aprinoia Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.21 Mil. Aprinoia Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-35.38 Mil. Aprinoia Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.54.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aprinoia Therapeutics's Debt-to-EBITDA or its related term are showing as below:

APRI's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Aprinoia Therapeutics  (NAS:APRI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Aprinoia Therapeutics Debt-to-EBITDA Related Terms

Aprinoia Therapeutics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Debt-to-EBITDA Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.05 -0.10 -0.82

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA N/A 0.00 -0.10 -1.44 -0.54

APRI vs : Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Debt-to-EBITDA falls into.


Aprinoia Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aprinoia Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(18.78 + 0.208) / -23.094
=-0.82

Aprinoia Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(18.78 + 0.208) / -35.378
=-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.54 mean?
Aprinoia Therapeutics (APRI) has a Debt-to-EBITDA of -0.54 as of Dec. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aprinoia Therapeutics.
Is Aprinoia Therapeutics' Debt-to-EBITDA too high?
Aprinoia Therapeutics' current Debt-to-EBITDA is -0.54.
How does Aprinoia Therapeutics' Debt-to-EBITDA compare to ?
Aprinoia Therapeutics' Debt-to-EBITDA of -0.54 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aprinoia Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current Debt-to-EBITDA is -0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Debt-to-EBITDA of -0.54. The current Debt-to-EBITDA is -0.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Debt-to-EBITDA is -0.54 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.